Giuseppe Curigliano, MD, PhD, University of Milan, Milan, Italy, outlines future directions in the treatment and management of patients with hormone receptor-positive (HR+) metastatic breast cancer, including how the results of the monarchE study (NCT03155997), a study of abemaciclib plus endocrine therapy in the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer, will shape the treatment of this patient population. This interview took place during the 17th St. Gallen International Breast Cancer Conference.